| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | — | Loop Capital | Upgrades | Hold → Buy | |
| 05/23/2023 | -12.81% | Wells Fargo | $66 → $55 | Maintains | Equal-Weight |
| 05/09/2023 | 26.82% | BMO Capital | $100 → $80 | Maintains | Outperform |
| 05/05/2023 | 4.63% | Wells Fargo | $80 → $66 | Maintains | Equal-Weight |
| 05/05/2023 | 1.46% | Loop Capital | $92 → $64 | Downgrades | Buy → Hold |
| 04/17/2023 | 26.82% | Wells Fargo | $85 → $80 | Maintains | Equal-Weight |
| 03/24/2023 | 45.85% | Loop Capital | $100 → $92 | Maintains | Buy |
| 03/01/2023 | 34.75% | Wells Fargo | $76 → $85 | Maintains | Equal-Weight |
| 02/02/2023 | 58.53% | Loop Capital | $81 → $100 | Upgrades | Hold → Buy |
| 01/09/2023 | 20.48% | Wells Fargo | $73 → $76 | Maintains | Equal-Weight |
| 11/04/2022 | 15.73% | Wells Fargo | $67 → $73 | Maintains | Equal-Weight |
| 10/18/2022 | 6.21% | Wells Fargo | $74 → $67 | Maintains | Equal-Weight |
| 10/11/2022 | 37.92% | BMO Capital | $89 → $87 | Maintains | Outperform |
| 05/09/2022 | 17.31% | Wells Fargo | $70 → $74 | Maintains | Equal-Weight |
| 10/29/2021 | 33.16% | Wells Fargo | $82 → $84 | Maintains | Equal-Weight |
| 07/29/2021 | 50.6% | Oppenheimer | $85 → $95 | Maintains | Outperform |
| 05/04/2021 | 74.38% | BMO Capital | $100 → $110 | Maintains | Outperform |
| 08/06/2020 | 33.16% | BMO Capital | $79 → $84 | Maintains | Outperform |
| 07/31/2020 | 4.63% | Stifel | $55 → $66 | Upgrades | Hold → Buy |
| 05/01/2020 | -12.81% | Wells Fargo | $43 → $55 | Maintains | Equal-Weight |
| 04/30/2020 | 3.04% | Oppenheimer | $80 → $65 | Maintains | Outperform |
| 04/03/2020 | -31.83% | Wells Fargo | → $43 | Downgrades | Overweight → Equal-Weight |
| 03/24/2020 | -33.42% | Stifel | $67 → $42 | Maintains | Hold |
| 02/21/2020 | 6.21% | Stifel | $76 → $67 | Maintains | Hold |
| 01/24/2020 | — | Loop Capital | Upgrades | Hold → Buy | |
| 12/06/2019 | 52.19% | Loop Capital | → $96 | Downgrades | Buy → Hold |
| 10/16/2019 | 58.53% | Wells Fargo | → $100 | Initiates Coverage On | → Outperform |
| 09/27/2019 | 101.33% | BMO Capital | $131 → $127 | Maintains | Outperform |
| 09/25/2019 | 56.94% | Stifel | $109 → $99 | Maintains | Hold |
| 09/05/2019 | — | Loop Capital | Upgrades | Hold → Buy | |
| 07/19/2019 | 69.63% | Jefferies | $129 → $107 | Downgrades | Buy → Hold |
| 07/18/2019 | — | BMO Capital | Initiates Coverage On | → Outperform | |
| 05/28/2019 | — | Berenberg | Upgrades | Hold → Buy | |
| 05/28/2019 | 74.38% | Berenberg | $120 → $110 | Upgrades | Hold → Buy |
| 04/08/2019 | 106.09% | Oppenheimer | $110 → $130 | Maintains | Outperform |
| 12/11/2018 | 33.16% | Stifel | → $84 | Initiates Coverage On | → Hold |
| 07/27/2018 | 74.38% | Keybanc | $95 → $110 | Maintains | Overweight |
What is the target price for Ingevity (NGVT)?
The latest price target for Ingevity (NYSE: NGVT) was reported by Loop Capital on July 27, 2023. The analyst firm set a price target for $0.00 expecting NGVT to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ingevity (NGVT)?
The latest analyst rating for Ingevity (NYSE: NGVT) was provided by Loop Capital, and Ingevity upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Ingevity (NGVT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ingevity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ingevity was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
Is the Analyst Rating Ingevity (NGVT) correct?
While ratings are subjective and will change, the latest Ingevity (NGVT) rating was a upgraded with a price target of $0.00 to $0.00. The current price Ingevity (NGVT) is trading at is $63.08, which is out of the analyst's predicted range.